A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Influence of Skeletal Muscle Volume Loss During Lenvatinib Treatment on Prognosis in Unresectable Hepatocellular Carcinoma: A Multicenter Study in Tohoku, Japan
Sarcopenia is associated with poor prognosis of patients with hepatocellular carcinoma (HCC). We investigated the association of skeletal muscle volume (SMV) and its change in HCC patients taking lenvatinib. In 132 HCC patients, psoas mass index (PMI) was calculated as the left-right sum of the vertical × horizontal diameter of psoas muscle at the third lumbar vertebra, divided by height squared. Patients were classified into two groups (low and normal PMI) based on indices of <6.0 cm2/m2 fordoi:10.21203/rs.3.rs-1325658/v1 fatcat:eu3jldn77jeodjmbnekkdc645a